Is Ruxolitinib Apotec Approved for Polycythemia Vera?
Yes, Ruxolitinib Apotec, a generic version of ruxolitinib (Jakafi), can be prescribed for adults with polycythemia vera (PV) who have an inadequate response to or are intolerant of hydroxyurea. This matches the FDA-approved indication for branded ruxolitinib, as generics must demonstrate bioequivalence to enter the market.[1]
How Does Ruxolitinib Work in PV?
Ruxolitinib inhibits JAK1 and JAK2 enzymes, reducing spleen size, improving symptoms like fatigue and night sweats, and lowering hematocrit levels in PV patients. Clinical trials (RESPONSE and RESPONSE-2) showed 21-49% of patients achieved hematocrit control without phlebotomy after 24 weeks, compared to 1% on best available therapy.[2][1]
Who Makes Ruxolitinib Apotec and When Did It Launch?
Apotex Inc. manufactures Ruxolitinib Apotec. It launched in the US in March 2024 following FDA approval of their Abbreviated New Drug Application (ANDA), after settling patent litigation with Incyte Corp., the originator of Jakafi.[3][4]
When Do Patents on Ruxolitinib Expire?
Key US patents for ruxolitinib (e.g., method-of-use for PV under US 8,158,616) expire in 2028, with pediatric exclusivity extending to January 2029. Formulation patents end earlier in 2026. Apotex gained entry via a settlement allowing launch at-risk before full expiry. Check DrugPatentWatch.com for the latest litigation status and expiration dates.[5]
What About Other Generics or Competitors?
Other generics include Mylan (now Viatris) and Celltrion, approved in 2023-2024. No biosimilars exist, as ruxolitinib is a small-molecule drug. Alternatives for PV include hydroxyurea (first-line), interferon alfa, or busulfan, but ruxolitinib is preferred for hydroxyurea failures per NCCN guidelines.[1][6]
Common Side Effects and Patient Concerns
Patients report thrombocytopenia (49%), anemia (40%), diarrhea (20%), and infections. Long-term risks include non-melanoma skin cancers and herpes zoster. Monitor blood counts closely; dosage starts at 10 mg twice daily, adjusted for platelets.[1][2] PV patients should discuss cardiovascular risks with their hematologist, as JAK inhibitors carry FDA warnings.
[1]: FDA Label for Ruxolitinib (Jakafi), https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202117s039lbl.pdf
[2]: Vannucchi et al., RESPONSE-2 Trial, NEJM 2018, https://www.nejm.org/doi/full/10.1056/NEJMoa1706227
[3]: FDA Orange Book, Ruxolitinib Approvals, https://www.accessdata.fda.gov/scripts/cder/ob/
[4]: Apotex Press Release, March 2024, https://www.apotex.com/us/about-us/news/2024/03/19/apotex-launches-generic-jakafi
[5]: DrugPatentWatch.com, Ruxolitinib Patents, https://www.drugpatentwatch.com/p/tradename/JAKAFI
[6]: NCCN Guidelines for Myeloproliferative Neoplasms, Version 2.2024, https://www.nccn.org/guidelines